Irinotecan (CPT-11)-induced hemorrhagic colitis / 대한내과학회지

ABSTRACT

Irinotecan (CPT-11) is a chemotherapeutic agent that inhibits topoisomerase I and has shown efficacy against advanced colorectal cancer. Diarrhea is the most common toxicity that has been reported to be as high as 87% in patients treated with irinotecan. However, the serious complications including acute hemorrhagic colitis, intestinal ulceration, and intestinal perforation may be uncommon events with irinotecan therapy. We report the first Korean case of acute hemorrhagic colitis induced by irinotecan administration in the patient with advanced colon cancer.